Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 31, 2022 09:30 ET | Source: Cullinan Metals Corp.

Cullinan Metals Options Lithium Property, Thunder Bay, ON

VANCOUVER, British Columbia, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Cullinan Metals Corp. (CSE: CMT), (OTC: CMTNF), (FWB: 7KO) ("Cullinan" or the “Company) is pleased to announce that it has entered into...
October 20, 2022 09:00 ET | Source: Cullinan Metals Corp.

Cullinan Metals Options a Graphite Property in Quebec

VANCOUVER, British Columbia, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Cullinan Metals Corp. (CSE: CMT) ("Cullinan" or the “Company”) is pleased to announce that it has entered into an option agreement (the...
January 10, 2022 06:30 ET | Source: Cullinan Oncology, Inc.

Cullinan Oncology Forms Strategic Collaboration Agreement with Mount Sinai to Advance Oral HPK1 Protein Degrader for Cancer Treatment

Collaboration to identify and advance best-in-class HPK1 protein degraders Exclusive option for Cullinan to license related intellectual property from the collaboration CAMBRIDGE, Mass., Jan. ...
January 05, 2022 09:00 ET | Source: Cullinan Oncology, Inc.

Cullinan Oncology to Present at Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that it will present at the following virtual healthcare conferences in...
January 04, 2022 07:00 ET | Source: Cullinan Oncology, Inc.

FDA Grants Breakthrough Therapy Designation for Cullinan Oncology’s CLN-081 in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted...
December 16, 2021 06:30 ET | Source: Cullinan Oncology, Inc.

Cullinan Oncology Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in...
December 13, 2021 07:00 ET | Source: Cullinan Oncology, Inc.

Cullinan Oncology to Provide Clinical Update for CLN-081 in NSCLC EGFR Exon 20 Patients

CAMBRIDGE, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology therapies,...
October 17, 2018 08:45 ET | Source: Cemtrex Inc.

Cemtrex Announces Settlement of Class Action Securities Lawsuit & Derivative Actions

Farmingdale, NY, Oct. 17, 2018 (GLOBE NEWSWIRE) -- – Cemtrex Inc. (Nasdaq: CETX, CETXP, CETXW), a world leading technology and manufacturing company, announced today that the Company has agreed to...